Pre-existing immunity to human parainfluenza virus (hPIV) does not affect rSIV.F/HN-mediated transduction efficiency by Pytel, K, Chan, M, Meng, C, Martinez, A, Boyd, C, Davies, J, Gill, D, Hyde, S, Innes, A, Alton, E, Griesenbach, U

Preparation for a first-in-man lentivirus trial in cystic fibrosis patients by Griesenbach, U, Alton, E, Beekman, J, Boyd, C, Davies, J, Davies, L, Dekkers, J, Gill, D, Hasegawa, M, Higgins, T, Hironaka, T, Inoue, M, Hyde, S, Innes, A, Pringle, I, Pytel, K, Sumner-Jones, S, Tsugumine, S, Wasowicz, M

The lung as a factory to produce secreted intrapulmonary and circulatory proteins by Paul-Smith, M, Pytel, K, Gelinas, J, McIntosh, J, Pringle, I, Davies, L, Bell, R, Cammack, L, Moran, C, Cameron, L, Inoue, M, Tsugumine, S, Hironaka, T, Gill, D, Hyde, S, Nathwani, A, Alton, E, Griesenbach, U

The murine lung as a factory to produce secreted intrapulmonary and circulatory proteins by Paul-Smith, M, Pytel, K, Gelinas, J, McIntosh, J, Pringle, I, Davies, L, Chan, M, Meng, C, Bell, R, Cammack, L, Moran, C, Cameron, L, Inoue, M, Tsugumine, S, Hironaka, T, Gill, D, Hyde, S, Nathwani, A, Alton, E, Griesenbach, U

Moving lentiviral-based gene therapy into a first-in-man CF trial by Griesenbach, D, Alton, E, Beekman, J, Boyd, A, Chan, M, Davies, J, Davies, L, Davidson, H, Dekkers, F, Gea-Sorli, S, Gill, D, Hasegawa, M, Higgins, T, Hyndman, L, McLachlan, G, Inoue, M, Hyde, S, Moran, C, Meng, C, Paul-Smith, M, Pringle, I, Pytel, K, Rodriguez-Martinez, A, Stevenson, B, Tsugumine, S

Preparation for a first-in-man lentivirus trial in patients with cystic fibrosis. by Alton, E, Beekman, J, Boyd, A, Brand, J, Carlon, M, Connolly, M, Chan, M, Conlon, S, Davidson, H, Davies, J, Davies, L, Dekkers, J, Doherty, A, Gea-Sorli, S, Gill, D, Griesenbach, U, Hasegawa, M, Higgins, T, Hironaka, T, Hyndman, L, McLachlan, G, Inoue, M, Hyde, S, Innes, J, Maher, T, Moran, C, Meng, C, Paul-Smith, M, Pringle, I, Pytel, K, Rodriguez-Martinez, A, Schmidt, A, Stevenson, B, Sumner-Jones, S, Toshner, R, Tsugumine, S, Wasowicz, M, Zhu, J

Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial by Alton, EWFW, Armstrong, DK, Ashby, D, Bayfield, K, Bilton, D, Bloomfield, E, Boyd, A, Brand, J, Buchan, R, Calcedo, R, Carvelli, P, Chan, M, Cheng, S, Collie, D, Cunningham, S, Davidson, H, Davies, G, Davies, J, Davies, L, Dewar, M, Doherty, A, Donovan, J, Dwyer, N, Elgmati, H, Featherstone, R, Gavino, J, Gea-Sorli, S, Geddes, D, Gibson, J, Gill, D, Greening, A, Griesenbach, U, Hansell, D, Harman, K, Higgins, T, Hodges, S, Hyde, S, Hyndman, L, Innes, J, Jacob, J, Jones, S, Keogh, B, Limberis, M, Lloyd-Evans, P, Maclean, A, Manvell, M, McCormick, D, McGovern, M, McLachlan, G, Meng, C, Montero, M, Milligan, H, Moyce, L, Murray, G, Nicholson, A, Osadolor, T, Parra-Leiton, J, Porteous, D, Pringle, I, Punch, E, Pytel, K, Quittner, A, Rivellini, G, Saunders, C, Scheule, R, Sheard, S, Simmonds, N, Smith, K, Smith, S, Soussi, N, Soussi, S, Spearing, E, Stevenson, B, Sumner-Jones, S, Turkkila, M, Ureta, R, Waller, M, Wasowicz, M, Wilson, J, Wolstenholme-Hogg, P